InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

- Current share price for NTI : $0.015

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$23 Investor Presentation 20 Mar 2023 9:57AM $0.058 $0.015 fallen by 75%
$23 NTI to Launch Phase II Clinical Trial in Rett Syndrome 20 Mar 2023 9:03AM $0.058 $0.015 fallen by 75%
$23 Investor Conference Call - 52 Week Autism Study Results 17 Mar 2023 10:01AM $0.058 $0.015 fallen by 75%
$23 Investor Presentation 17 Mar 2023 9:53AM $0.058 $0.015 fallen by 75%
$23 Phase I/II ASD Clinical Trials Results at 52 Weeks 17 Mar 2023 9:45AM $0.058 $0.015 fallen by 75%
$23 Trading Halt 15 Mar 2023 9:45AM $0.058 $0.015 fallen by 75%
$23 Notification of cessation of securities - NTI 1 Mar 2023 7:53PM $0.054 $0.015 fallen by 73.15%
$23 Notification regarding unquoted securities - NTI 28 Feb 2023 8:03PM $0.051 $0.015 fallen by 71.57%
$23 Appendix 4D and Half Year Accounts 28 Feb 2023 4:59PM $0.051 $0.015 fallen by 71.57%
$23 First Patient Treated in Phase I/II PANDAS/PANS Trial 16 Feb 2023 11:27AM $0.054 $0.015 fallen by 73.15%
$23 Approval for Additional Phase I/II ASD Trial Extension 14 Feb 2023 10:11AM $0.056 $0.015 fallen by 74.11%
$23 Secondary Trading Notice 31 Jan 2023 7:12PM $0.075 $0.015 fallen by 80.67%
$23 Application for quotation of securities - NTI 31 Jan 2023 6:39PM $0.075 $0.015 fallen by 80.67%
$23 Top 20 securityholders 31 Jan 2023 6:34PM $0.075 $0.015 fallen by 80.67%
$23 Distribution Schedule 31 Jan 2023 6:33PM $0.075 $0.015 fallen by 80.67%
$23 Application for quotation of securities - NTI 31 Jan 2023 6:28PM $0.075 $0.015 fallen by 80.67%
$23 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2023 9:40AM $0.071 $0.015 fallen by 79.58%
$23 HREC Approval for Phase I/II PANDAS/PANS Clinical Trial 27 Jan 2023 9:33AM $0.071 $0.015 fallen by 79.58%
$23 Secondary Trading Notice 24 Jan 2023 7:08PM $0.069 $0.015 fallen by 78.99%
$23 Application for quotation of securities - NTI 24 Jan 2023 6:57PM $0.069 $0.015 fallen by 78.99%
$23 Notice of Quarterly Investor Conference Call 24 Jan 2023 6:45PM $0.069 $0.015 fallen by 78.99%
$23 NTI Granted FDA Pre-IND Meeting for NTI164 in ASD 19 Jan 2023 11:30AM $0.072 $0.015 fallen by 79.86%
$23 Extension of Offers under Prospectus 13 Jan 2023 1:57PM $0.067 $0.015 fallen by 78.36%
$23 Change of Director's Interest Notice x2 28 Dec 2022 8:00PM $0.070 $0.015 fallen by 79.29%
$23 Notification regarding unquoted securities - NTI 23 Dec 2022 7:19PM $0.070 $0.015 fallen by 79.29%

251 - 275 of 694 results

Page 11 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.